Simulation-Based Patient Education to Address Radiotherapy-Related Anxiety in Cancer Patients (ARAISE) (ARAISE)
Addressing Radiotherapy Anxiety Through Immersive Simulation and Education: Effects of a Simulation-Based Patient Education Intervention on Psychosocial Burden in Cancer Patients Receiving Radiotherapy (ARAISE)
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Rami El Shafie, Prof. Dr. med
- Numer telefonu: +49 551 3964501
- E-mail: rami.elshafie@med.uni-goettingen.de
Kopia zapasowa kontaktu do badania
- Nazwa: Stephan-Peter Landgraff, M.Ed.
- Numer telefonu: +49 30 76 68 37 5 600
- E-mail: stephan.landgraff@medicalschool-berlin.de
Lokalizacje studiów
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Niemcy, 37075
- Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen
-
Kontakt:
- Stephan-Peter Landgraff, M.Ed.
- Numer telefonu: +49 5513964501
- E-mail: stephan.landgraff@medicalschool-berlin.de
-
Kontakt:
- Rami El Shafie, Prof. Dr. med.
- Numer telefonu: +49 5513964501
- E-mail: rami.elshafie@med.uni-goettingen.de
-
Główny śledczy:
- Rami El Shafie, Prof. Dr. med.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Age 18 years or older
- Histologically or cytologically confirmed malignant tumor disease
- Stage I - III (UICC TNM classification)
- ECOG performance status ≤ 2
- Curative-intent external beam radiotherapy regimen with at least 5 fractions
- First course of radiotherapy
- Able to independently operate the electronic data collection instrument
- Written informed consent after study information
- Sufficient German language proficiency to read and complete the study questionnaires independently and without translation assistance
Exclusion Criteria:
- Lack of capacity to provide informed consent
- Pregnancy or breastfeeding
- Stereotactic radiotherapy
- Emergency treatment indication
- Acute suicidality, acute psychosis, or other acute psychiatric disorder
- Initiation of or dose change in psychotropic medication within 4 weeks before baseline (T0)
- Cognitive impairment that precludes independent completion of the questionnaires
- Visual or auditory impairment that prevents perception of the on-screen or audio content despite available aids
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Brak interwencji: Standard Patient Education
Participants receive standard patient education before radiotherapy according to routine clinical practice.
Standard patient education comprises the physician consultation covering the indication and aim of radiotherapy, treatment planning and delivery, possible acute and late side effects, and organizational aspects of care.
No simulation-based education session is provided.
Prescribed oncological treatment and routine radiotherapy care are not altered.
|
|
|
Eksperymentalny: Simulation-Based Patient Education
Participants receive standard patient education as in the control arm and, in addition, a single structured simulation-based patient education session after the planning CT and before the first radiotherapy fraction.
|
A single, standardized, simulation-based patient education session lasting 15 to 20 minutes, conducted in addition to the standard education session that takes place after the planning CT scan and before the first radiation therapy fraction.
This session uses the immersive radiation therapy simulation software VERT 9.0 to visualize the treatment room, the linear accelerator, and the treatment process.
In addition to illustrating the treatment process, targeted information is provided to address treatment-specific fears identified as priorities in the Delphi consensus.
The session is conducted by the principal investigator following a standardized procedure to ensure comparability among participants.
The prescribed oncological treatment and routine radiation therapy remain unchanged.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
State anxiety at the first radiotherapy fraction (STAI-G Form X1)
Ramy czasowe: First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
State anxiety at the first radiotherapy fraction (T2), measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G).
The sum score comprises 20 items and ranges from 20 to 80, with higher scores indicating greater state anxiety.
The adjusted between-group difference in means at T2 is analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
The effect measure is the adjusted mean difference with a 95% confidence interval.
|
First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
State anxiety after the planning CT or education session (STAI-G Form X1)
Ramy czasowe: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
State anxiety at T1, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G).
Scores range from 20 to 80, with higher scores indicating greater state anxiety.
Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
|
T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
|
State anxiety at the fifth radiotherapy fraction (STAI-G Form X1)
Ramy czasowe: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
State anxiety at T3, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G).
Scores range from 20 to 80, with higher scores indicating greater state anxiety.
Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
|
Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
|
Health-related quality of life: Global Health Status/Quality of Life (EORTC QLQ-C30)
Ramy czasowe: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
Health-related quality of life at T3, measured with the EORTC QLQ-C30 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater global health status and quality of life.
Analyzed by analysis of covariance with group as a factor, the T0 Global Health Status/Quality of Life score as a continuous covariate, and dichotomized trait anxiety at T0 as a factor.
Functioning and symptom scales are reported descriptively only.
|
Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
|
Perceived amount of information received: "Information about the treatment" scale (EORTC QLQ-INFO25)
Ramy czasowe: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
Perceived amount of information received at T1, measured with the multi-item scale "Information about the treatment" (items 38 to 43) of the EORTC QLQ-INFO25 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater perceived amount of information.
Groups are compared in a linear model with group as a factor and dichotomized trait anxiety at T0 as the only adjustment variable.
The remaining multi-item scales, single items, the total score, and the assessment at T2 are reported descriptively.
|
T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
|
Feasibility of the simulation-based patient education intervention
Ramy czasowe: From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
|
Composite descriptive endpoint with target values defined a priori: recruitment rate of at least 50%, retention rate of at least 80% at T3, protocol adherence of at least 90%, data completeness of at least 85% from T0 to T3, and tolerability defined as discontinuation due to intervention-associated distress reactions in no more than 10% of participants.
All rates are reported with two-sided 95% confidence intervals.
No formal hypothesis testing is performed.
|
From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Moderation of the intervention effect on state anxiety at T2 by trait anxiety
Ramy czasowe: First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Dispositional trait anxiety is measured once at baseline (T0) with the trait scale (Form X2) of the German version of the State-Trait Anxiety Inventory (STAI-G) and dichotomized at a threshold of 40 points or higher.
The group-by-trait-anxiety interaction term is tested in the analysis of covariance model of the primary endpoint (state anxiety at T2). Dichotomized trait anxiety additionally serves as a stratification factor for randomization and as a prognostic factor in all analyses of state anxiety.
This analysis is not independently powered and is interpreted as hypothesis-generating.
|
First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
|
Effect modification of the primary endpoint by prespecified participant and treatment characteristics
Ramy czasowe: First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Effect modification of state anxiety at T2 by irradiation site (central nervous system, head and neck, breast, thorax, abdomen, pelvis), sex, educational level, and concomitant systemic therapy, assessed via the respective interaction terms with treatment allocation in the model of the primary endpoint.
These analyses are not independently powered and are interpreted as hypothesis-generating.
|
First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Rami El Shafie, Prof. Dr. med., Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen (UMCG)
- Dyrektor Studium: Stephan-Peter Landgraff, M.Ed., Faculty of Health Sciences, Medical School Berlin (MSB)
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- ARAISE-RT-UMG-2026
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .